Entity

Time filter

Source Type

Shreveport, LA, United States

Shackelford R.E.,LSU Health Shreveport | Mayhall K.,Tulane University | Maxwell N.M.,Independent Researcher | Kandil E.,Tulane University | Coppola D.,H. Lee Moffitt Cancer Center and Research Institute
Genes and Cancer | Year: 2014

Nicotinamide phosphoribosyltransferase (Nampt) catalyzes the rate-limiting step of nicotinamide adenine dinucleotide (NAD) synthesis. Both intracellular and extracellular Nampt (iNampt and eNampt) levels are increased in several human malignancies and some studies demonstrate increased iNampt in more aggressive/invasive tumors and in tumor metastases. Several different molecular targets have been identified that promote carcinogenesis following iNampt overexpression, including SirT1, CtBP, and PARP-1. Additionally, eNampt is elevated in several human cancers and is often associated with a higher tumor stage and worse prognoses. Here we review the roles of Nampt in malignancy, some of the known mechanisms by which it promotes carcinogenesis, and discuss the possibility of employing Nampt inhibitors in cancer treatment. © The Author(s) 2013. Source


Kolluru G.K.,LSU Health Shreveport | Majumder S.,University of Rochester | Chatterjee S.,Anna University
Nitric Oxide - Biology and Chemistry | Year: 2014

Rho GTPases are a globular, monomeric group of small signaling G-protein molecules. Rho-associated protein kinase/Rho-kinase (ROCK) is a downstream effector protein of the Rho GTPase. Rho-kinases are the potential therapeutic targets in the treatment of cardiovascular diseases. Here, we have primarily discussed the intriguing roles of ROCK in cardiovascular health in relation to nitric oxide signaling. Further, we highlighted the biphasic effects of Y-27632, a ROCK inhibitor under shear stress, which acts as an agonist of nitric oxide production in endothelial cells. The biphasic effects of this inhibitor raised the question of safety of the drug usage in treating cardiovascular diseases. © 2014 Elsevier Inc. All rights reserved. Source


Schwendimann R.N.,LSU Health Shreveport
Neurologic Clinics | Year: 2013

This review article identifies and describes the clinical manifestations of various metabolic, nutritional, and toxic conditions that result in symptoms of myelopathy and, in some cases, myeloneuropathy. It includes discussions of the clinical pictures that occur secondary to these causes. Familiarity with the clinical symptoms may lead to accurate diagnosis through laboratory and imaging studies and to treatment with successful identification of the underlying causes. © 2013 Elsevier Inc. Source


Shackelford R.E.,LSU Health Shreveport | Vora M.,LSU Health Shreveport | Mayhall K.,Tulane University | Cotelingam J.,LSU Health Shreveport
Genes and Cancer | Year: 2015

The anaplastic lymphoma tyrosine kinase (ALK) gene was first described as a driver mutation in anaplastic non-Hodgkin’s lymphoma. Dysregulated ALK expression is now an identified driver mutation in nearly twenty different human malignancies, including 4-9% of non-small cell lung cancers (NSCLC). The tyrosine kinase inhibitor crizotinib is more effective than standard chemotherapeutic agents in treating ALK positive NSCLC, making molecular diagnostic testing for dysregulated ALK expression a necessary step in identifying optimal treatment modalities. Here we review ALKmediated signal transduction pathways and compare the molecular protocols used to identify dysregulated ALK expression in NSCLC. We also discuss the use of crizotinib and second generation ALK tyrosine kinase inhibitors in the treatment of ALK positive NSCLC, and the known mechanisms of crizotinib resistance in NSCLC. © 2015, Impact Journals LLC. All rights reserved. Source


Gungor A.A.,LSU Health Shreveport | Reiersen D.A.,LSU Health Shreveport
American Journal of Otolaryngology - Head and Neck Medicine and Surgery | Year: 2014

Congenital nasal piriform aperture stenosis (CNPAS) is an uncommon but important cause of nasal obstruction in infants. When it is severe, nasal decongestants or temporary nasal airway devices cannot address the problem adequately. The most common surgical technique used to treat the bony piriform aperture stenosis is the sublabial approach and drill-out of the nasal aperture followed by nasal stenting. This paper describes an infant with bilateral CNPAS who underwent a single successful balloon dilatation and short-term stenting of the nasal piriform apertures without the need for additional procedures. © 2014 Elsevier Inc. Source

Discover hidden collaborations